share_log

Sana Biotechnology | 10-Q: Q3 2024 Earnings Report

Sana Biotechnology | 10-Q: Q3 2024 Earnings Report

Sana Biotechnology | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/08 22:19

Moomoo AI 已提取核心訊息

Sana Biotechnology reported a net loss of $59.9 million for Q3 2024, compared to net income of $1.0 million in Q3 2023. Total operating expenses were $61.8 million, with research and development expenses of $53.2 million. The company ended the quarter with $199.0 million in cash, cash equivalents, and marketable securities.The company announced a strategic repositioning to focus on type 1 diabetes, B-cell mediated autoimmune diseases, refractory B-cell malignancies, and fusogen platform development. As part of this restructuring, Sana will suspend development of SC291 in oncology and SC379 glial progenitor cell program while seeking partnerships. The reorganization includes a 45% workforce reduction expected to be completed in Q1 2025.In February 2024, Sana completed an underwritten public offering raising approximately $180.0 million through the sale of 21.8 million shares of common stock and pre-funded warrants to purchase 12.7 million shares. The company expects to incur approximately $6.4 million in severance and related costs due to the workforce reduction, with operating losses and expenses projected to decrease in 2025 compared to 2024.
Sana Biotechnology reported a net loss of $59.9 million for Q3 2024, compared to net income of $1.0 million in Q3 2023. Total operating expenses were $61.8 million, with research and development expenses of $53.2 million. The company ended the quarter with $199.0 million in cash, cash equivalents, and marketable securities.The company announced a strategic repositioning to focus on type 1 diabetes, B-cell mediated autoimmune diseases, refractory B-cell malignancies, and fusogen platform development. As part of this restructuring, Sana will suspend development of SC291 in oncology and SC379 glial progenitor cell program while seeking partnerships. The reorganization includes a 45% workforce reduction expected to be completed in Q1 2025.In February 2024, Sana completed an underwritten public offering raising approximately $180.0 million through the sale of 21.8 million shares of common stock and pre-funded warrants to purchase 12.7 million shares. The company expects to incur approximately $6.4 million in severance and related costs due to the workforce reduction, with operating losses and expenses projected to decrease in 2025 compared to 2024.
Sana生物技術報告了2024年第三季度淨虧損爲5990萬美元，相較於2023年第三季度的凈利潤100萬美元。總營業費用爲6180萬美元，其中研發費用爲5320萬美元。公司在季度末擁有現金、現金等價物和可交易證券19900萬美元。公司宣佈戰略重組，專注於1型糖尿病億.cell介導的自身免疫疾病、頑固性b細胞惡性腫瘤和融合平台開發。作爲這次重組的一部分，Sana將暫停在腫瘤學中的SC291開發和SC379膠質細胞前體程序，同時尋求合作伙伴。此次重組包括預計在2025年第一季度完成的45%員工削減。2024年2月，Sana完成了一項承銷的公開發行，通過出售2180萬股普通股和預融資認股權證爲購買1270萬股募集了約18000萬美元。由於員工削減，公司預計將產生約640萬美元的裁員及相關費用，預計2025年的營業虧損和費用將比2024年減少。
Sana生物技術報告了2024年第三季度淨虧損爲5990萬美元，相較於2023年第三季度的凈利潤100萬美元。總營業費用爲6180萬美元，其中研發費用爲5320萬美元。公司在季度末擁有現金、現金等價物和可交易證券19900萬美元。公司宣佈戰略重組，專注於1型糖尿病億.cell介導的自身免疫疾病、頑固性b細胞惡性腫瘤和融合平台開發。作爲這次重組的一部分，Sana將暫停在腫瘤學中的SC291開發和SC379膠質細胞前體程序，同時尋求合作伙伴。此次重組包括預計在2025年第一季度完成的45%員工削減。2024年2月，Sana完成了一項承銷的公開發行，通過出售2180萬股普通股和預融資認股權證爲購買1270萬股募集了約18000萬美元。由於員工削減，公司預計將產生約640萬美元的裁員及相關費用，預計2025年的營業虧損和費用將比2024年減少。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！